Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 + NALIRIFOX +/- Adebrelimab as Neoadjuvant Therapy for Pancreatic Cancer
NCT07691593Phase 2Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Jun 2026
- Primary completion
- Oct 2027
01
Overview
A Phase 2 trial of HRS-4642 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Changhai Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
HRS-4642
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07691593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691593.